Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

6,335

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

6,335 results for “direct”

Learn how ShareScore rates datasets ↗
geo16/100

Targeting glycolysis reduces infection and dampens inflammation in a host-directed therapy for dengue

GEO Series GSE203176. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2025View details →
geo16/100

Transcription factor Ascl2 promotes geminal center B cell responses through directly regulating AID transcription

GEO Series GSE169416. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenMar 2021View details →
geo16/100

Direct-induced human retinal ganglion cells mimic fetal RGCs and are neuroprotective after transplant in vivo

GEO Series GSE200452. Homo sapiens. 1 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2022View details →
geo16/100

Analysis of HER2 genomic binding in breast cancer cells identifies a global role in direct gene regulation

GEO Series GSE79778. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenJul 2018View details →
geo16/100

Direct regulation of myocardial triglyceride metabolism by the cardiomyocyte circadian clock

GEO Series GSE21028. Mus musculus. 19 samples. Type: Expression profiling by array.

openGEO-OpenMar 2010View details →
geo16/100

Chemically synthesized guide RNAs can direct CRISPR-CasRx cleavage of circRNAs with high efficiency and specificity

GEO Series GSE189963. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2023View details →
geo16/100

Directional RNA-Seq analysis of Arabidopsis plants grown under Pi-deprived conditions

GEO Series GSE70095. Arabidopsis thaliana. 4 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2016View details →
geo16/100

Integrin αEβ7+ T cells direct intestinal stem cell fate decision via adhesive signaling

GEO Series GSE135316. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2022View details →
geo16/100

Ikaros and Aiolos directly regulate AP-1 transcriptional complexes and are essential for natural killer cell development [RNA-seq]

GEO Series GSE247282. Mus musculus. 21 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2023View details →
zenodo16/100

Dataset related to article "Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis."

<p>PURPOSE:</p> <p>The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT).</p> <p>METHODS:</p> <p>In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT.</p> <p>RESULTS:</p> <p>119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2&nbsp;months. Rates of OS at 1 and 3&nbsp;years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3&nbsp;years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3&nbsp;years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3&nbsp;years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34&nbsp;months (3&nbsp;years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI&thinsp;&lt;&thinsp;34&nbsp;months (3&nbsp;years DPFS 9.1%); Class 2: DFI&thinsp;&gt;&thinsp;34&nbsp;months and high-risk NCCN PC (3&nbsp;years DPFS 21%); Class 3: DFI&thinsp;&gt;&thinsp;34&nbsp;months and low-intermediate risk NCCN disease (3&nbsp;years DPFS 60.2%).</p> <p>CONCLUSION:</p> <p>Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.</p>

restrictedMar 2020View details →
zenodo16/100

Dataset related to article "Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"

<p>This record contains raw data related to article &ldquo;Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance&quot;</p> <p><strong>Introduction:&nbsp;</strong>In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves).</p> <p><strong>Patients and methods:&nbsp;</strong>We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age &gt; 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival.</p> <p><strong>Results:&nbsp;</strong>A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010).</p> <p><strong>Conclusion:&nbsp;</strong>Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.</p>

restrictedDec 2020View details →
zenodo16/100

Surface Porosity Prediction in Directed-Energy-Deposition (DED) Printed SS316L Parts

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Nov 2023View details →
zenodo16/100

Salt marsh fairy circles are directional ellipses rather than circles

<p><span>A dataset of 3,544 distinct fairy circles, complete with images and their attributes. Moreover, we determined the aspect ratio as the minor axis length divided by the major axis length, and the areas of equivalent axis-length ellipses and equal perimeter circles.</span></p>

restrictedcc-by-4.0Mar 2024View details →
zenodo16/100

The Wave Acquisition Stereo System data in support of Directional Breaking Kinematics Observations from 3D Stereo Reconstruction of Ocean Waves

<p>The &nbsp;stereo-image data archived at https://data-dataref.ifremer.fr/stereo/AA_2015/2015-03-05_10-35-00_12Hz/ has been processed with the Wave Acquisition Stereo System (WASS) software and the output is resampled to a regular grid of 20 cm for the computation of Wave Spectrum.</p> <p>The data is in standard Netcdf4 format and include metadata. The python script used to generate this .nc file is available at https://github.com/akaawase-bernard/WASSnc</p> <p>There is a total of 21571 snapshots of the sea surface elevation information.</p>

restrictedcc-by-4.0Apr 2024View details →
zenodo16/100

Dataset related to article "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer"

<p>This record contains raw data related to article &quot;Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer&quot;</p> <p><strong>Introduction:&nbsp;</strong>Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We aimed to evaluate outcome of oligometastatic HNC treated with Stereotactic body radiotherapy (SBRT) as metastasis-directed therapy.</p> <p><strong>Materials and methods:&nbsp;</strong>We analyzed patients treated with SBRT on a maximum of five oligometastases from HNC, in up to two organs. Concomitant treatment was allowed. End points were toxicity, local control of treated metastases (LC), progression-free survival (PFS) and overall survival (OS).</p> <p><strong>Results:&nbsp;</strong>48 consecutive patients and 71 lesions were treated. With a follow-up of 20.2 months, most common primary tumors were larynx (29.2%) and salivary glands (29.2%), while common site of metastases was lung (59.1%). Median dose was 48 Gy (21-75) in 3-8 fractions. Treatment was well tolerated, with two patients reporting mild pain and nausea. LC rates at 1 and 2 years were 83.1% and 70.2%. Previous local therapy (HR 4.97; p = 0.002), oligoprogression (HR 4.07; p = 0.031) and untreated metastases (HR 4.19; p = 0.027) were associated with worse LC. PFS at 1 and 2 years were 42.2% and 20.0%. Increasing age (HR 1.03; p = 0.010), non-adenoid cystic carcinoma (HR 2.57; p = 0.034) and non-lung metastases (HR 2.20; p = 0.025) were associated with worse PFS. One- and 2-years OS were 81.0% and 67.1%. Worse performance status (HR 2.91; p = 0.049), non-salivary primary (HR 19.9; p = 0.005), non-lung metastases (HR 2.96; p = 0.040) were correlated with inferior OS.</p> <p><strong>Conclusions:&nbsp;</strong>SBRT can be considered a safe metastasis-directed therapy in oligometastatic HNC. Efficacy of the treatment seems to be higher when administered upfront in the management of metastatic disease; however, selection of patients need to be improved due to the relevant risk of appearance of new metastatic site after SBRT.</p>

restrictedJan 2021View details →
zenodo16/100

Dataset related to article "Direct effects of octreotide on osteoblast cell proliferation and function"

<p>This record contains data related to article&quot;&nbsp;Direct effects of octreotide on osteoblast cell proliferation and function<strong>&quot;.</strong></p> <p>&nbsp;</p> <p><em>Purpose.</em> Octreotide (OCT) is a first-generation somatostatin analog (SSA) used in the treatment of acromegaly and neuroendocrine tumors (NETs). In both diseases, OCT interacts with somatostatin receptors 2 and 5 (SSTR2 and SSTR5), inhibiting hormone hypersecretion and cell proliferation. Skeletal health is an important clinical concern with acromegaly and NETs since acromegalic osteopathy and NET bone metastasis occur in a remarkable number of patients. While OCT&rsquo;s effect on NET cells has been extensively investigated, its direct action on bone cells remains unknown.</p> <p><em>Methods.</em> Here we investigated OCT direct effects on cell proliferation, differentiation, mineralization, and chemoattractant capacity of murine primary osteoblasts and osteoblast cell line MC3T3-E1.</p> <p><em>Results.</em> OCT inhibited osteoblasts and MC3T3-E1 cell proliferation (-30% &plusmn; 16%, and -22 &plusmn; 4%, both p&lt;0.05) and increased MC3T3-E1 cell apoptosis (+76 &plusmn; 32%, p&lt;0.05 vs control).</p> <p>The anti-proliferative action of OCT was mediated by SSTR2 and SSTR5 in MC3T3-E1, while its proapoptotic effect was abrogated in SSTR2-silenced cells. The analysis of genes related to the early and late phases of osteoblast differentiation showed that OCT did not affect <em>Alp, Runx2</em>, <em>Bglap, Spp1, and Sost </em>levels in MC3T3-E1 cells. Similarly, OCT had no effect on ALP activity and mineralization in osteoblasts. In addition, <em>Vegfa</em> expression decreased in OCT-treated MC3T3-E1 cells and OCT inhibited pancreatic NET cell migration towards osteoblast-conditioned medium.</p> <p><em>Conclusion.</em>This study provides the first evidence of the direct action of &nbsp;OCT on osteoblasts which may have clinically relevant implications for the management of skeletal health in subjects with acromegaly and metastatic NETs.</p>

restrictedJun 2022View details →
zenodo16/100

Dataset related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection"

<p>This record contains raw data related to article &quot;Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients&#39; selection&quot;</p> <p>&nbsp;</p> <p>Abstract: Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease. Aim of the present study was to analyze oligoprogressive prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) during systemic treatment to identify predictive factors and improve patients&#39; selection. We included PC patients treated with SBRT on a maximum of 3 sites of oligoprogression during systemic therapy. Endpoints were freedom from polymetastatic progression (FPP), local control (LC), distant progression free survival (DPFS), overall survival (OS), and next systemic therapy free survival (NEST-FS). Fifty-three patients were treated on 85 oligoprogressive metastases. Lymph nodes were the most common sites (56.47%), followed by bone (39.29%). Median follow-up was 24.9 months. Rates of FPP at 1- and 2-year were 80.1% and 68.9%, respectively. Median time to polymetastatic progression was 33.7 months. Disease free interval (p = 0.004), site of metastases (p = 0.011), and type of systemic therapy (p = 0.003) were significant for FPP. Switch or intensification of systemic therapy after SBRT was observed in 29 (54.72%) patients with a median NEST-FS of 15.2 months. LC at 1- and 2-year was 94.0% and 92.0%, with PSA doubling time resulted to be significantly associated (p = 0.047). Median DPFS was 8.93 months and median OS was 50.6 months. In conclusion, we confirmed the efficacy of SBRT for oligoprogression from PC, with the potential to prolong the on-going systemic therapy and interrupt the metastatic cascade.</p>

restrictedOct 2022View details →
zenodo16/100

Supplementary Tables - U-Pb direct dating on calcite paleosol nodules by LA-ICP-MS mapping: first absolute age constraints on the Miocene continental succession of the Paris Basin

<p>Supplementary data table from the manuscript U-Pb direct dating on calcite paleosol nodules by LA-ICP-MS mapping: first absolute age constraints on the Miocene continental succession of the Paris Basin.</p> <p>For each table, the processed data of chemical and isotopic composition is presented along with criteria used to define the ROI, pooling channel, information on map size and relevant pictures of map and ROI selection. Geochronology results are presented in the three system mentioned in the method part of the manuscript.</p> <p>In each file the first thumbnail is the results of QC material DBT, while the second thumbnail is the sample, if there is more than two thumbnail, that mean that the sample provided multiple zonations which were datable.</p>

restrictedcc-by-4.0Apr 2024View details →
zenodo16/100

Dataset related to paper: Estimation through direct turbulence measurements of the Nocturnal Boundary Layer Height over the Central Amazon Forest.

<p>This dataset contains one year (2022) of observational data collected at the ATTO ( Amazon Tall Tower Observatory) Project in the Central Amazon region. Please consult the README file for a description of the dataset.</p>

restrictedcc-by-4.0May 2024View details →
zenodo16/100

Hepatocellular Carcinoma incidences and risk factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents

<p><span>Table S1: </span><span>Comparisons of baseline clinical characteristics between patients treated with DAA and IFN after propensity score matching.</span></p> <p><span>Table S2: </span><span>Univariate and multivariate cox regression model for HCC after propensity score matching</span><span>.</span></p> <p><span>Table S3: </span><span>Univariate and multivariate cox regression model for early HCC (&lt;3 years)</span><span>.</span></p> <p><span>Table S4: </span><span>Univariate and multivariate cox regression model for late HCC (3-6 years)</span><span>. </span></p> <p><span>Figure S1: Flowchart of patient recruitment.</span></p> <p><span>Figure S2: Scheme for time scale in Cox regression analysis to investigate early HCC and late HCC predictors.</span></p> <p><span>Figure S3: The cumulative HCC incidences stratified by age </span><span><span>&sup3;</span></span><span>60 and &lt;60 years</span><span> (A) in ACLD (B) in non-ACLD</span></p> <p><span>Figure S4: The comparisons of the HCC risks within 3 years (early onset) and after 3 years (late onset). (A) DAA group (B) IFN group. </span></p>

restrictedcc-by-4.0Aug 2024View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.